Gilead Sciences Inc logo

Gilead Sciences Inc

GILD
Healthcare|Drug Manufacturers - General|USA
$140.13
+0.42 (+0.30%)
DCF (FCF)
$82.91
Earnings Power
$67.72

Upcoming Data Readouts (45)

Aug 2026
Est. completion
P2Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565n=100
Aug 2026
Est. completion
P3Disseminated Histoplasma Capsulatum Infection
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
NCT05814432n=279
Sep 2026
Est. completion
P2Chronic Hepatitis B
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150n=150
Sep 2026
Est. completion
P3Ulcerative Colitis
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
NCT02914535n=1,173
Oct 2026
Est. completion
P2Solid Tumor
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907n=53
Nov 2026
Est. completion
P2Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
NCT06329869n=35
Nov 2026
Est. completion
P2Ovarian Carcinoma
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
NCT06028932n=20
Nov 2026
Est. completion
P2NSCLC Stage IV
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
NCT06401824n=25
Dec 2026
Est. completion
P2Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885n=136
Dec 2026
Est. completion
P1Advanced or Metastatic Solid Tumor
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522n=30
Dec 2026
Est. completion
NAOvarian Cancer
Comprehensive Outcomes for After Cancer Health
NCT05349227n=625
Dec 2026
Est. completion
P1Gastrointestinal Cancer
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
NCT06065371n=20
Dec 2026
Est. completion
P2Endometrial Carcinoma
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04251416n=50
Dec 2026
Est. completion
NAHIV Infections
Teamwork Makes the Dream Work
NCT05866523n=250
Jan 2027
Est. completion
P2Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766n=332
Jan 2027
Est. completion
P2Ulcerative Colitis
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972n=176
Jan 2027
Est. completion
P4HIV Prevention
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
NCT07218211n=100
Jan 2027
Est. completion
P3Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968n=614
Feb 2027
Est. completion
Fungal Disease
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
NCT07357038n=38
Mar 2027
Est. completion
P2Locally Advanced Gastric Adenocarcinoma
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
NCT06250036n=50

Awaiting Results (17)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026
P1
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
NCT06079164
Jul 2026
P2
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329
Jun 2026
P3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095
May 2026
P1P2
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096
May 2026
P1
Study of GS-0272 in Participants With Rheumatoid Arthritis
NCT06031415
Feb 2026
P2
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
Dec 2025
P1
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Sep 2025
P2P3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341
Jun 2025
P2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530
Feb 2025
NA
Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study
NCT06353295

Recent Press Releases